Effects of Artemisia annua-Sublingual Immunotherapy on Asthma Control and Pulmonary Function in Patients with Mild-Moderate Allergic Asthma
International Archives of Allergy and Immunology · 26.02.2025 · 186 (10) · 956-966
DOI: 10.1159/000543864 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 26.02.2025. Verfasst von Chong Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiration, General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Asthma, Sublingual Immunotherapy, Allergens, Artemisia annua. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Introduction
The aim of this study was to observe and assess the efficacy and safety of Artemisia annua (A. annua)-sublingual immunotherapy (SLIT) in patients with mild-moderate allergic asthma (AS).
Methods
In this retrospective study, the complete data of 60 patients with mild-moderate AS from October 2022 to October 2023 were included. Patients were stratified into two different groups based on treatment regimens: the SLIT group, 30 individuals who underwent standardized A. annua-SLIT for at least 6 months before pollen season, and the control group, the other 30 patients only received the symptomatic drug. During the 2022 and 2023 pollen season, asthma daytime symptom score (ADSS), asthma nighttime symptom score (ANSS), total medicine score (TMS), asthma control test score (ACT), forced expiratory volume in 1 s (FEV1), and FEV1/forced vital capacity were measured to evaluate the efficacy, and adverse events (AEs) were used to assess its safety.
Results
There were no significant differences in all clinical outcomes between the two groups during the 2022 pollen season (all p > 0.05). However, after SLIT treatment, the level of ADSS, ANSS, TMS, ACT, FEV1, and patients’ number of well-controlled AS significantly improved compared with the control group (all p < 0.01). Notably, all the clinical outcomes significantly improved compared with the baseline only in the SLIT group (all p < 0.001). No severe AEs were reported, and all AEs were mild.
Conclusion
Pre-seasonal treatment of A. annua-SLIT for at least 6 months could relieve daytime and nighttime symptoms, reduce medication use, and improve asthma control and lung function in mono- and polysensitized patients with mild-moderate AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiration, General Hospital of Northern Theater Command, Shenyang, China.
- China Medical University, Shenyang, China.
Zitieren
APA
Xu, C., Zhao, Y., Huang, H., Zou, H., Qian, Y., Wang, X., Guan, W., Zhang, M., Ma, H., Xu, C., & Chai, R. (2025). Effects of Artemisia annua-Sublingual Immunotherapy on Asthma Control and Pulmonary Function in Patients with Mild-Moderate Allergic Asthma. International Archives of Allergy and Immunology, 186(10), 956-966. https://doi.org/10.1159/000543864
Vancouver
Xu C, Zhao Y, Huang H, Zou H, Qian Y, Wang X, et al. Effects of Artemisia annua-Sublingual Immunotherapy on Asthma Control and Pulmonary Function in Patients with Mild-Moderate Allergic Asthma. International Archives of Allergy and Immunology. 2025;186(10):956-966. doi:10.1159/000543864
BibTeX
@article{Xu2025,
author = {Xu, Chong and Zhao, Yumeng and Huang, Hehua and Zou, Hongmei and Qian, Yuqing and Wang, Xinzhuo and Guan, Wenchao and Zhang, Min and Ma, Huijuan and Xu, Chong and Chai, Ruonan},
title = {Effects of Artemisia annua-Sublingual Immunotherapy on Asthma Control and Pulmonary Function in Patients with Mild-Moderate Allergic Asthma},
journal = {International Archives of Allergy and Immunology},
year = {2025},
volume = {186},
number = {10},
pages = {956--966},
doi = {10.1159/000543864}
}
EUVIMED